The WuXi Biologics, Eli Lilly and Alexandria Real Estate Equities-backed cancer therapy developer is targeting $74.7m in its IPO.
US-based biologic drug developer Inhibrx has filed for a $74.7m initial public offering that will enable pharmaceutical development services provider WuXi Biologics and pharmaceutical firm Eli Lilly to exit.
Previously known as Tenium Therapeutics, Inhibrx has created a protein engineering platform it is using to develop treatments for diseases including cancer.
The company will use the IPO proceeds to complete phase 1 clinical trials of cancer drug candidates INBRX-109 and INBRX-105, and to begin a phase 1 trial of…
